실적 발표 분석으로 건너뛰기
← 피드로 돌아가기
GL FY2025 Q4 IMPROVING

Globe Life Inc. 실적 발표

Feb 05, 2026 · 06:00 ET Frank SabotaMatt DardenMike Majors
Buzzberg 분석

2026 EPS guidance raised, expecting 5% growth at midpoint

Globe Life reported strong FY2025 earnings and raised 2026 guidance, driven by robust growth in health (particularly Medicare supplement) and improving life margins. Management highlighted a structural shift from Medicare Advantage to Med Supp, the launch of a Bermuda reinsurer for capital efficiency, and continued agent productivity gains. FY2025 net operating income per share $14.52, slightly above prior guidance midpoint; Q4 EPS $3.39 (+8% YoY).

Buzzberg 분석 2026 EPS guidance raised, expecting 5% growth at midpoint Globe Life reported strong FY2025 earnings and raised 2026 guidance, driven by robust growth in health (particularly Medicare supplement) and improving life margins. Management highlighted a structural shift from Medicare Advantage to Med Supp, the launch of a Bermuda reinsurer for capital efficiency, and continued agent productivity gains. FY2025 net operating income per share $14.52, slightly above prior guidance midpoint; Q4 EPS $3.39 (+8% YoY). 전체 분석 보기분석 접기

Globe Life reported strong FY2025 earnings and raised 2026 guidance, driven by robust growth in health (particularly Medicare supplement) and improving life margins. Management highlighted a structural shift from Medicare Advantage to Med Supp, the launch of a Bermuda reinsurer for capital efficiency, and continued agent productivity gains. FY2025 net operating income per share $14.52, slightly above prior guidance midpoint; Q4 EPS $3.39 (+8% YoY).

  • 2026 EPS guidance $14.95–$15.65 (midpoint +5% YoY, normalized +10%), raised versus prior outlook.
  • Health premium growth guided to 14–16% in 2026, driven by strong Med Supp sales and rate increases; United American sales doubled in 2025.
  • Life premium growth accelerating to 4–4.5% in 2026, supported by agent count recovery and DTC lead conversion improvements.
Revenue $1.5239B +1% QoQ
EPS $3.39 -30% QoQ
Gross margin 30.36% reported
LIFE op margin 41% reported

이번 분기에 달라진 점

01
Guidance

2026 EPS guidance raised, expecting 5% growth at midpoint

Guidance · revenue to 7.5%

02
Growth

Health premium revenue to grow 14-16% in 2026

FY2025 net operating income per share $14.52, slightly above prior guidance midpoint; Q4 EPS $3.39 (+8% YoY).

03
Sales

United American MedSupp sales nearly doubled in 2025

2026 EPS guidance $14.95–$15.65 (midpoint +5% YoY, normalized +10%), raised versus prior outlook.

04
Capital Management

Bermuda reinsurer formed, initial $1.2B reserves transferred

Health premium growth guided to 14–16% in 2026, driven by strong Med Supp sales and rate increases; United American sales doubled in 2025.

수요 및 자본지출

수요

수주 및 전환

Management raised 2026 EPS guidance citing continued favorable mortality trends, strong sales momentum across multiple distribution channels, and a constructive outlook for Medicare supplement. Normalized EPS growth of ~10% underpins a confident tone.

자본지출

투자 및 생산능력

Management discussed continued technology investments aimed at improving agent productivity and direct-to-consumer lead conversion, with more enhancements expected in 2026 and 2027, but provided no specific capital expenditure figures.

톤 · Confident

Management expressed confidence in growth opportunities across divisions, citing strong sales momentum, favorable mortality trends, and strategic initiatives like the Bermuda reinsurance entity, while acknowledging manageable headwinds such as agent turnover and health margin mix.

공급망 알파

A1

A major shift in the Medicare market is underway: beneficiaries are moving from Medicare Advantage plans to Medicare Supplement plans due to MA reimbursement cuts and provider network constraints, fueling Globe Life's 50% sales surge at United American in 2025.

“We attribute this tremendous growth primarily to the significant movement of Medicare beneficiaries from Medicare Advantage plans to Medicare Supplement plans.”
Matt Darden
A2

Globe Life launched a Bermuda reinsurance subsidiary, transferring $1.2B of statutory reserves in 2025, and expects to grow annual parent cash flow toward $200M as the block builds, enhancing capital flexibility without relying on US subsidiary dividends.

“We anticipate parents' annual excess cash flow will increase over time toward $200 million as earnings emerge from reinsurance additional, in-force, and new business.”
Tom Kombach

향후 가이던스

ImprovingGuidance · revenue to 7.5% · was IN LINE last Q
향후 가이던스
지표기간범위중간값상태
EPSFY2026$14.95–$15.65$15.30RAISED
Free cash flowFY2026$0.625B–$0.675B$0.65BRAISED
Op marginLIFEFY202641.5%–44.5%43%INITIATED
Op marginHEALTHFY202623%–27%25%INITIATED
RevenueHEALTHFY202614%–16%15%INITIATED
RevenueFY20267%–8%7.5%INITIATED
RevenueLIFEFY20264%–4.5%4.25%INITIATED

가이던스 신뢰도

1 / 1달성 또는 상회
가이던스 신뢰도
제시 시점지표목표 기간가이던스실제결과
FY2025 Q3EPSFY2025$14.40–$14.60$14.52Met / beat

기업 영향 분석

+47.2%
발표 이후
$271.12$399.05
발표 이후
+26.7%
발표 이후
$76.82$97.35
공급망공급망 알파

A major shift in the Medicare market is underway: beneficiaries are moving from Medicare Advantage plans to Medicare Supplement plans due to MA reimbursement cuts and provider network constraints, fueling Globe Life's 50% sales surge at United American in 2025. — This structural shift pressures MA carriers (UNH, HUM, CVS) on enrollment and margins, while benefiting Med Supp writers like Globe Life.